Literature DB >> 31914799

Prior Case of Resistance on Dolutegravir Plus Lamivudine Dual Therapy.

Babafemi O Taiwo1, Miguel E Quiñones-Mateu2, Kimberly Smith3, Lu Zheng4, Roy Gulick5, Amesika N Nyaku6, Paul E Sax7, Belinda Ha3, Johnstone Kumwenda8, Maxine Olefsky4, Catherine Godfrey9, Carole Wallis10.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 31914799      PMCID： PMC7185366          DOI： 10.1089/AID.2019.0253

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN： 0889-2229            Impact factor:   2.205


× No keyword cloud information.
  4 in total

1.  Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials.

Authors:  Pedro Cahn; Juan Sierra Madero; José Ramón Arribas; Andrea Antinori; Roberto Ortiz; Amanda E Clarke; Chien-Ching Hung; Jürgen K Rockstroh; Pierre-Marie Girard; Jörg Sievers; Choy Man; Alexander Currie; Mark Underwood; Allan R Tenorio; Keith Pappa; Brian Wynne; Anna Fettiplace; Martin Gartland; Michael Aboud; Kimberly Smith
Journal:  Lancet       Date:  2018-11-09       Impact factor: 79.321

2.  ACTG A5353: A Pilot Study of Dolutegravir Plus Lamivudine for Initial Treatment of Human Immunodeficiency Virus-1 (HIV-1)-infected Participants With HIV-1 RNA <500000 Copies/mL.

Authors:  Babafemi O Taiwo; Lu Zheng; Andrei Stefanescu; Amesika Nyaku; Baiba Bezins; Carole L Wallis; Catherine Godfrey; Paul E Sax; Edward Acosta; David Haas; Kimberly Y Smith; Beverly Sha; Cornelius Van Dam; Roy M Gulick
Journal:  Clin Infect Dis       Date:  2018-05-17       Impact factor: 9.079

3.  Sensitive deep-sequencing-based HIV-1 genotyping assay to simultaneously determine susceptibility to protease, reverse transcriptase, integrase, and maturation inhibitors, as well as HIV-1 coreceptor tropism.

Authors:  Richard M Gibson; Ashley M Meyer; Dane Winner; John Archer; Felix Feyertag; Ezequiel Ruiz-Mateos; Manuel Leal; David L Robertson; Christine L Schmotzer; Miguel E Quiñones-Mateu
Journal:  Antimicrob Agents Chemother       Date:  2014-01-27       Impact factor: 5.191

4.  Perspectives on the Barrier to Resistance for Dolutegravir + Lamivudine, a Two-Drug Antiretroviral Therapy for HIV-1 Infection.

Authors:  Marta Boffito; Laura Waters; Pedro Cahn; Roger Paredes; Justin Koteff; Jean Van Wyk; Tia Vincent; James Demarest; Kimberly Adkison; Romina Quercia
Journal:  AIDS Res Hum Retroviruses       Date:  2019-10-21       Impact factor: 2.205
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.